Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma
Despite its encouraging early efficacy, the administration of BV-DHAP in Korean patients with RRHL requires careful monitoring due to toxicity concerns.
Authors
- Young Hoon Park (ORCID: https://orcid.org/0000-0003-4516-7990)
- Kwai Han Yoo (ORCID: https://orcid.org/0000-0002-3049-9055)
- Junshik Hong (ORCID: https://orcid.org/0000-0002-7829-397X)
- Myung-Won Lee
- Jun Yi (ORCID: https://orcid.org/0000-0003-2526-9674)
- Hyeon-Seok Eom
Institutions
- Gachon University (KR)
- Ewha Womans University (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- National Cancer Center (US)
- Chungnam National University Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Blood Research
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1007/s44313-025-00097-z
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47